Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat

Digestive Diseases and Sciences

Volumn 43, Issue 9, 1998, Pages 2055-2060

  Izadnia, Fariba ^a   Wong, Catarina Tse ^a   Kocoshis, Samuel A ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Clostridium difficile; Colonic secretion; Saccharomyces boulardii; Saccharomyces cerevisiae

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; DIARRHEA; INTESTINE MUCOSA PERMEABILITY; INTESTINE SECRETION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE;

ANIMALS; CECUM; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INTESTINAL MUCOSA; MALE; MANNITOL; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE; SODIUM; WATER;

EID: 0031713422     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018811331596     Document Type: Article

References (33)

1. Surawicz C, Elmer G, Speelman P, McFarland L, Chinn J and Belle G: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology 96:981-988, 1989
2. Bartlett JG: Clostridium difficile: Pseudomembranous colitis and antibiotic-associated diarrhea. In Infectious Diarrhea. SL Gorbach (ed). Boston, Massachusetts, Blackwell Scientific Publications, 1986, pp 157-178
3. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD: Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47(2):349-352, 1985
4. Tabaqchali S, Jumaa P: Diagnosis and management of Clostridium difficile infection. BMJ 310:1375-1380, 1995
5. Gröschel D: Clostridium difficile infection. Crit Rev Clin Lab Sci 33(3):203-245, 1996
6. Fekety R: Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 92(5):739-750, 1997
7. Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, Kelly CP: Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41:366-370, 1997
8. Wedel N, Toselli P, Pothoulakis C, Faris B, Oliver P, Franzblau C, Lamont T: Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts. Exp Cell Res 148:413-422, 1983
9. Sullivan NM, Pellett S, Wilkins TD: Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun 35(1):1032-1040, 1982
10. Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT: Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93:273-279, 1987
11. Pothoulakis G, Sullivan DA, Melnick AJ, Gadenne T, Meshulam T, LaMont JT: Clostridium difficile toxins A and B stimulate intracellular calcium release in human neutrophils. Clin Res 34:530A, 1986
12. Lyerly DM, Lockwood PE, Richardson SH, Wilkins TD: Biological activities of toxins A and B of Clostridium difficile. Infect Immun 35:1147-1150, 1982
13. Settle CD, Wilcox MH: Review article: Antibiotic-induced Clostridium difficile infection. Aliment Pharmacol Ther 10:835-841, 1996
14. Wenisch B, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W: Clin Infect Dis 22:813-818, 1996
15. Schwan A, Sjolins S, Trottestam U, Aronsson B: Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 16:211-215, 1984
16. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL: Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 21:224-226, 1995
17. Surawicz C, McFarland L, Elmer G, Chinn J: Treatment of Recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 84(10):1285-1287, 1989
18. Castex F, Corthier G, Jouvert S, Elmer G, Lucas F, Bastide M: Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: A scanning electron microscopic and microbiological study. J Gen Microbiol 136:1085-1089, 1990
19. Maejima K, Shimoda K, Morita C, Fujiwara T, Kitamura T: Colonization and pathogenicity of Saccharomyces cerevisiae, MC16, in mice and cynomolgus monkeys after oral and intravenous administration. Jpn J Med Sc Biol 33:271-276, 1980
20. Schellenberg D, Bonington A, Champion C, Lancaster R, Webb S, Main J: Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 343:171, 1994
21. Kocoshis SA, Dawson SJ, Tse Wong C: Bismuth subsalicylate and montmorillonite prevent bile-acid-induced colonic secretion in the rat. Curr Ther Res 43(1):32-42, 1988
22. Isenberg HD, Washington II JA, Balows A, Sonnenwirth AC: Collection, handling, and processing of specimens. In Manual of Clinical Microbiology. EH Lennette (ed). Washington, DC, American Society for Microbiology, 1985, pp 73-98
23. Donowitz M, Binder HJ: Effects of dioctyl sodium sulfosuccinate on colonic fluid and electrolyte movement. Gastroenterology 69(4):941-950, 1975
24. Pothoulakis C, Kelly CP, Joshi M, Gao N, O'Keane CJ, Castagliuolo I, Lamont T: Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104:1108-1115, 1993
25. Reisch JS: Statistical considerations for clinical research. In Techniques of patient-oriented research. CYC Pak, PM Adams (eds). New York, Raven Press, 1994, pp 97-100
26. Buts J, Bernasconi P, Vaerman J, Dive C: Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35(2):251-256, 1990
27. Czerucka D, Roux I, Rampal P: Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106:65-72, 1994
28. Eng R, Drehmel R, Smith S, Goldstein E: Saccharomyces cerevisiae infections in man. J Med Vet Mycol 22:403-407, 1984
29. Sobel JD, Vazquez J, Lynch M, Meriwether C, Zervos MJ: Vaginitis due to Saccharomyces cerevisiae'. Epidemiology, clinical aspects, and therapy. Clin Infect Dis 16:93-99, 1993
30. Giaffer MH, Clark A, Holdsworth CD: Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut 33:1071-1075, 1992
31. Barnes RMR, Allan S, Taylor-Robinson CH, Finn R, Johnson PM: Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: Is IgA antibody a marker for Crohn's Disease? Int Arch Allergy Appl Immunol 92:9-15, 1990
32. McKenzie H, Main J, Pennington CR, Parratt D: Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 31:536-538, 1990
33. Young CA, Sonnenberg A, Burns EA: Lymphocyte proliferation response to baker's yeast in Crohn's disease. Digestion 55:40-43, 1994